97 related articles for article (PubMed ID: 9807165)
1. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols.
Dorr RT; Bellamy W; Liddil JD; Baker A; Bair KW
Anticancer Drug Des; 1998 Oct; 13(7):825-35. PubMed ID: 9807165
[TBL] [Abstract][Full Text] [Related]
2. Production of protein-associated DNA breaks by 10-[diethylaminopropylamino]-6-methyl-5H-pyrido[3',4':4,5]pyrrolo [2,3-g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors.
Pierson V; Pierre A; Pommier Y; Gros P
Cancer Res; 1988 Mar; 48(6):1404-9. PubMed ID: 2830964
[TBL] [Abstract][Full Text] [Related]
3. 8-methoxycaffeine-induced protein-associated DNA breaks in isolated L1210 cell nuclei.
Zignaigo G; Vigani A; Billi G; Brega I; Piccini D; Poggi L; Parodi S; Russo P
Boll Soc Ital Biol Sper; 1990 Jun; 66(6):587-94. PubMed ID: 2175203
[TBL] [Abstract][Full Text] [Related]
4. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
5. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors.
Han S; Xiao Z; Bastow KF; Lee KH
Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972
[TBL] [Abstract][Full Text] [Related]
6. Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells.
Carter CA; Bair KW
Invest New Drugs; 1991 May; 9(2):125-36. PubMed ID: 1874597
[TBL] [Abstract][Full Text] [Related]
7. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a)quinolinium with DNA topoisomerases: a possible-mechanism for its biological activity.
Báez A; Riou JF; Le Pecq JB; Riou G
Mol Pharmacol; 1990 Mar; 37(3):377-82. PubMed ID: 2156151
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
9. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW
Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
[TBL] [Abstract][Full Text] [Related]
14. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
15. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
Constantinou AI; Husband A
Anticancer Res; 2002; 22(5):2581-5. PubMed ID: 12529967
[TBL] [Abstract][Full Text] [Related]
16. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.
Barret JM; Etiévant C; Baudouin C; Skov K; Charvéron M; Hill BT
Anticancer Res; 2002; 22(1A):187-92. PubMed ID: 12017285
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.
Adams DJ
Cancer Res; 1989 Dec; 49(23):6615-20. PubMed ID: 2819712
[TBL] [Abstract][Full Text] [Related]
19. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
20. Interactions of mitomycin C with mammalian DNA detected by alkaline elution.
Dorr RT; Bowden GT; Alberts DS; Liddil JD
Cancer Res; 1985 Aug; 45(8):3510-6. PubMed ID: 3926301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
